ALVAC HIV VCP205 DELIVERED BY ALTERNATE MUCOSAL ROUTES WITH BOOSTING HIV1 SF2

ALVAC HIV VCP205 通过替代粘膜途径输送，增强 HIV1 SF2

• 批准号: 6219580
• 负责人: BARNEY S GRAHAM
• 金额: $ 0.06万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6219580
• 关键词: AIDS vaccines; HIV envelope protein gp120; active immunization; clinical research; clinical trial phase I; drug screening /evaluation; human immunodeficiency virus 1; human subject; human therapy evaluation; mucosal immunity; oral mucosa; recombinant proteins

Evaluate the safety and immunogenicity of ALVAC-HIV vCP205 and HIV-1 SF rgp120. The vaccine is to be given to healthy HIV-1 unifected adult volunteers by alternative foutes of delivery to assess th edevelopment of mucosal immunity, followed by boosting with HIV-1 SF-2 rgp 120 delivered by the IM route. We are nearing recruitment and enrollment for this study. WE are focusing most of our efforts on follow up.

评价ALVAC-HIV vCP 205和HIV-1 SF rgp 120的安全性和免疫原性。 将通过替代给药途径将疫苗给予健康的HIV-1未感染成人志愿者，以评估粘膜免疫的发展，然后通过IM途径给予HIV-1 SF-2 rgp 120加强免疫。 我们即将完成本研究的招募和入组。我们把大部分精力集中在后续行动上。